Ambulatoria Za Individualna Praktika Za Specializirana Izvunbolnichna Medicinska Pomost Po Alergologia Doktor Talyat Sali Cholak EOOD
- Address
- Ulitsa Vasil Levski 1 Office 49, 7200 Razgrad, Bulgaria
Ambulatoria Dr. Talyat Sali Cholak - Specialized Allergology Center
Dr. Talyat Sali Cholak's specialized allergology practice is a dedicated clinical research center focused on advancing treatments for complex allergic and immunologic disorders. The center demonstrates extensive expertise in conducting innovative therapeutic trials, with particular emphasis on chronic urticaria subtypes and respiratory allergic diseases refractory to standard treatments.
- Chronic urticaria research including spontaneous and inducible subtypes with novel biologic therapies
- Severe asthma management and maintenance therapy reduction studies
- Pediatric and adult seasonal allergic rhinitis immunotherapy trials
The center specializes in evaluating cutting-edge biologic agents and immunomodulatory therapies for patients with H1-antihistamine refractory conditions. Their research portfolio includes phase 2 and phase 3 trials examining targeted therapies such as mast cell inhibitors, TSLP blockers, and sublingual immunotherapy. With expertise in managing both chronic spontaneous urticaria and chronic inducible urticaria, the practice conducts comprehensive provocation testing and disease activity monitoring using validated assessment tools like UAS7 scoring systems.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Chiesi Farmaceutici S.p.A.2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Celldex Therapeutics Inc.3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ambulatoria Za Individualna Praktika Za Specializirana Izvunbolnichna Medicinska Pomost Po Alergologia Doktor Talyat Sali Cholak EOOD
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria | Celldex Therapeutics Inc. | Phase III | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Barzolvolimab | 3 | Unknown | 2022-11-09 | 2026-04-20 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.